The New York Times
The personalized HIV therapy using minute, naturally occurring proteins called zinc fingers to engineer T cells to one day treat AIDS in humans -- pioneered by Carl June, MD, director of Translational Medicine at the Abramson Family Cancer Research Institute, and a professor of Pathology and Laboratory Medicine -- is featured in a New York Times article on the zinc-finger technology. A clinical trial is now under way to see if T cells from HIV patients would have their CCR5 gene deliberately cut out by a zinc finger molecule. These modified T cells are then infused back into the patients to re-establish their immune system and decrease their viral load. Katherine A. High, MD, a professor of pediatrics at Penn and Children's Hospital of Philadelphia, also commented in the article.